Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alejandro Diaz

Pediatric Endocrinology Miami, FL Medical Doctor

NPI 1821185869 CMS profile 355765

3100 Sw 62Nd Ave, Suite 102, Miami, FL 33155

Open in the dashboard

General payments

$100,925

424 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alejandro Diaz of Miami, FL is reported in the CMS Open Payments database as having received $100,925 across 424 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $76,167 85
2024 General $12,202 63
2023 General $1,825 64
2022 General $2,117 88
2021 General $908 34
2020 General $536 25
2019 General $7,172 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alejandro Diaz
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Alejandro Diaz were reported at $76,167. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Alejandro Diaz Pediatric Endocrinology median Middle half National median
2019 $7,172 $196 $68–$845 $163
2020 $536 $124 $37–$722 $114
2021 $908 $134 $35–$691 $132
2022 $2,117 $177 $47–$726 $149
2023 $1,825 $236 $75–$887 $160
2024 $12,202 $259 $91–$979 $164
2025 $76,167 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neurocrine Biosciences, Inc. $66,642 44 payments
  2. Novo Nordisk Inc $14,151 45 payments
  3. Genzyme Corporation $10,123 4 payments
  4. Eton Pharmaceuticals, Inc. $1,319 3 payments
  5. Insulet Corporation $1,212 53 payments
  6. Ascendis Pharma, Inc. $867 19 payments
  7. Sanofi-Aventis U.S. LLC $622 22 payments
  8. Tandem Diabetes Care, Inc. $588 18 payments
  9. Beta Bionics, Inc. $534 10 payments
  10. Alexion Pharmaceuticals, Inc. $523 15 payments
  11. Other $4,345 191 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $54,784 10 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $28,000 5 payments
  3. Food and Beverage $11,683 380 payments
  4. Travel and Lodging $6,208 20 payments
  5. Education $250 9 payments
Products named General payments · program years 2019–2025
  1. CRENESSITY $64,690 40 payments
  2. Sogroya $7,768 22 payments
  3. Norditropin $5,995 7 payments
  4. Alkindi $1,319 3 payments
  5. KHINDIVI $1,063 1 payment
  6. INCRELEX $1,063 1 payment
  7. Omnipod $874 34 payments
  8. SKYTROFA $689 16 payments
  9. TZIELD $622 22 payments
  10. t:slim X2 Insulin Pump with Control-IQ $492 13 payments
  11. Other $7,896 283 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

424 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record